Company Analysis
Sign in

Eledon Pharmaceuticals, Inc. (ELDN)

Nasdaq: ELDN · Pharmaceutical Preparations · Irvine, CA · filing with the SEC since 2007
Full chart Alerts Compare
Grade4.3
◀ Past 3.2● Present 5.0▶ Future 4.4
6 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

6 patents granted to the 3 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Eledon Pharmaceuticals, Inc.’s names, not what it holds today.

Patents granted
6
6 utility, 1976 to Dec 31, 2025
Granted in 2025
none
in the last year the record reads
Applications published
18
1 of them in 2025
Names they are printed under
3
a former name, its own name
By yearGrantedApplications published
'11'12'14'15'16'17'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
Under which name3 counted
Tokai Pharmaceuticals, Inc. a former name
US, as the owner printed on each patent
6 granted
7 published
Tokai Pharmaceuticals, Inc. a former name
named as the applicant on its applications, in US
0 granted
10 published
ELEDON PHARMACEUTICALS, INC. its own name
US, as the owner printed on each patent
0 granted
1 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Nov 7, 20179,808,472Biomarkers for treatment of neoplastic disorders using androgen-targeted therapiesPharmaceuticalsTokai Pharmaceuticals, Inc.
Jul 12, 20169,387,216Biomarkers for treatment of neoplastic disorders using androgen-targeted therapiesPharmaceuticalsTokai Pharmaceuticals, Inc.
Jun 7, 20169,359,395Prodrugs of steroidal CYP17 inhibitors/antiandrogensPharmaceuticalsTokai Pharmaceuticals, Inc.
Oct 13, 20159,156,878Treatment of prostate cancerPharmaceuticalsTokai Pharmaceuticals, Inc.
Jul 29, 20148,791,095Steroidal CYP17 inhibitors/antiandrogensPharmaceuticalsTokai Pharmaceuticals, Inc.
Jul 29, 20148,791,094Treatment of prostate cancerPharmaceuticalsTokai Pharmaceuticals, Inc.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Oct 30, 20252025/0334594METHODS FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSISPharmaceuticalsELEDON PHARMACEUTICALS, INC.
Jun 8, 20172017/0157148TREATMENT OF PROSTATE CANCERPharmaceuticalsTokai Pharmaceuticals, Inc.
Jan 12, 20172017/0008920MAMMALIAN METABOLITES OF STEROIDSPharmaceuticalsTokai Pharmaceuticals, Inc.
Feb 11, 20162016/0038511BIOMARKERS FOR TREATMENT OF NEOPLASTIC DISORDERS USING ANDROGEN-TARGETED THERAPIESPharmaceuticalsTokai Pharmaceuticals, Inc. · patent 9,808,472 granted from it
Jan 7, 20162016/0002283NOVEL COMPOSITIONS AND METHODS FOR TREATING PROSTATE CANCERPharmaceuticalsTokai Pharmaceuticals, Inc.
Dec 31, 20152015/0374721BIOMARKERS FOR TREATMENT OF NEOPLASTIC DISORDERS USING ANDROGEN-TARGETED THERAPIESPharmaceuticalsTokai Pharmaceuticals, Inc. · patent 9,387,216 granted from it
Nov 12, 20152015/0320770NOVEL COMPOSITIONS AND METHODS FOR TREATING PROSTATE CANCERPharmaceuticalsTokai Pharmaceuticals, Inc.
Jul 23, 20152015/0203528TREATMENT OF PROSTATE CANCERPharmaceuticalsTokai Pharmaceuticals, Inc.
Jun 18, 20152015/0166599TREATMENT OF PROSTATE CANCERPharmaceuticalsTokai Pharmaceuticals, Inc.
Feb 19, 20152015/0051179NOVEL STEROIDAL CYP17 INHIBITORS/ANTIANDROGENSPharmaceuticalsTokai Pharmaceuticals, Inc.
What it applied for, 2024 to 2025: Pharmaceuticals 1.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton ELDN · research, not advice